Supplement
The biology is plausible. The outcome trials do not exist.
Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Information is based on current medical literature and clinical guidelines but may not apply to your specific situation. Individual responses vary based on personal medical history and concurrent conditions. Always consult qualified healthcare providers for medical decisions. Never delay seeking medical care based on content you’ve read. If experiencing a medical emergency, seek immediate medical attention.
These articles provide education to enhance your healthcare partnership. All treatment decisions should involve your healthcare team. Use this knowledge to have informed discussions, not to replace medical care.
Safety note: Several supplements in this article carry documented interaction risks. Nattokinase has clot-dissolving activity that adds to the bleeding risk of anticoagulant or antiplatelet drugs. Alpha-lipoic acid can lower blood glucose, which matters for people on diabetes medications. High-dose cassia cinnamon contains coumarin, which is hepatotoxic at sustained high intake. L-carnitine raises a gut-derived metabolite, TMAO, that is associated with cardiovascular risk in observational studies. Each of these is worth disclosing to every prescriber, because the interaction is often the part the prescriber cannot see.
In brief: The ten compounds in this article — alpha-lipoic acid, chromium, cinnamon, nattokinase, taurine, L-carnitine, lycopene, policosanol, astaxanthin, and probiotics — share one profile: a biological rationale, modest effects on surrogate markers such as blood pressure or cholesterol in small studies, and no randomized trial designed to show that any of them prevents heart attacks, strokes, or cardiovascular death. For most, that outcome trial will likely never be run, because the compounds are unpatentable and such trials cost tens to hundreds of millions of dollars with no commercial return to fund them. A few have evidence for a non-cardiovascular indication — alpha-lipoic acid for diabetic nerve pain, chromium as a modest glucose adjunct in type 2 diabetes — that is separate from cardiovascular prevention. (1,2) Several carry interaction risks that matter clinically, particularly nattokinase combined with anticoagulant or antiplatelet drugs, high-dose cassia cinnamon and liver injury, and the unresolved TMAO question with L-carnitine. (4,6,12) Policosanol illustrates the category’s central caution: a single research group reported large cholesterol reductions across more than 80 trials that independent investigators could not reproduce. (8)
Where the Evidence Stands
These compounds share one defining feature: none has a cardiovascular outcome trial. What differs among them is the strength of the surrogate signal — a modest blood-pressure or glucose effect for some, little or nothing for others — and two carry an interaction caution: nattokinase with antithrombotic drugs, and high-dose cassia cinnamon with the liver. (4,12) Two have their stronger evidence outside cardiology altogether — alpha-lipoic acid for diabetic nerve pain and chromium for glucose control — which is a separate matter from cardiovascular prevention. (1,2) The Evidence at a Glance table below sets out the per-compound detail. This describes what the trials found; it is information for a conversation with a clinician, not a basis for self-directed treatment.
Find Your Situation
| If you… | What the evidence supports |
| Have diabetic nerve pain and saw alpha-lipoic acid marketed for the heart | Alpha-lipoic acid has randomized evidence for diabetic neuropathy symptoms and is a registered medicine for that indication in Germany; that is separate from cardiovascular prevention, where outcome evidence does not exist (1) |
| Have type 2 diabetes and want added glucose help | Chromium produced a small HbA1c reduction (about 0.6%) in type 2 diabetes, and cinnamon showed inconsistent glucose effects; both are adjuncts, not substitutes for proven diabetes medications, and neither has cardiovascular outcome data (2,3) |
| Are on warfarin, a DOAC (direct oral anticoagulant), or antiplatelet therapy | Nattokinase has clot-dissolving activity that adds to bleeding risk without proven cardiovascular benefit; the combination is one to raise explicitly with the prescriber (4) |
| Are considering policosanol for cholesterol | Independent trials did not reproduce the large LDL reductions reported by the original single-source research group; current evidence does not support it for cholesterol lowering (8) |
| Eat little or no red meat | Gut bacteria produce far less TMAO from L-carnitine in vegetarians and vegans, which is relevant context for the TMAO concern (6) |
| Want a supplement to lower blood pressure | Lycopene, taurine, and some probiotic strains show modest systolic reductions in small studies (roughly 4–5 mmHg or less), well below the effect of antihypertensive medication and with no outcome data (7,9,10) |
| Use daily cassia (grocery-store) cinnamon supplements | Cassia contains coumarin, which is hepatotoxic at sustained high intake; Ceylon cinnamon contains far less, and this distinction is worth discussing if supplementing daily (3,12) |
Why This Category Exists
Most cardiovascular supplements have never been tested in a trial designed to prove they prevent cardiovascular events, and most never will be.
The reason is financial, not scientific. A randomized trial powered to detect a reduction in heart attacks or strokes typically requires several thousand patients, several years of follow-up, and tens to hundreds of millions of dollars. Pharmaceutical companies fund such trials when there is a patentable molecule whose proven benefit will generate revenue that justifies the cost. None of the compounds in this article is patentable. Each is generic, naturally occurring, or long in use, so no entity stands to recover the cost of proving it works. The trial does not happen. The supplement stays on the shelf. Marketing presents the modest blood-pressure or cholesterol effects from small studies as though they were proof of cardiovascular benefit.
This evidence gap is structural rather than accidental, and most of what fills the cardiovascular supplement aisle lives inside it. The compounds that did get large outcome trials — vitamin D, B vitamins, antioxidants, niacin — were exceptions, tested because they had patent histories, public funding from agencies such as the NIH, or commercial interests that predated the modern supplement era. Those exceptions were tested and failed (Articles 8, 15, 16, 17). The compounds that never got the trial sit in a different category: not proven ineffective, not proven effective, simply untested at the level the rest of cardiovascular medicine treats as definitive.
The honest position for this category is uncertainty. That matters because the cardiovascular supplement industry generates billions in sales each year, much of it on claims the trial evidence does not support, and many people take these products believing the heart-attack-and-stroke question has already been answered. For the compounds here, it has not.
The Policosanol Lesson
Policosanol is a mixture of long-chain alcohols derived from sugar cane wax. Beginning in the 1990s, a Cuban research group published more than 80 placebo-controlled trials reporting LDL reductions in the range of 15–25% — effects rivaling prescription statins. (8) The supplement sold in more than 40 countries on the strength of that evidence base. The trials were peer-reviewed, appeared in legitimate journals, and were never specifically retracted. By a count-the-trials-and-the-effect-size standard, the case looked overwhelming.
When independent investigators outside Cuba tested it, the effect was not there. The Berthold trial, published in JAMA in 2006, tested Cuban sugar-cane-derived policosanol — supplied by the same source used in the Cuban studies — at 10, 20, 40, and 80 mg daily in 143 patients with hypercholesterolemia or combined hyperlipidemia, following a six-week placebo-and-diet run-in with a 12-week double-blind treatment phase. (8) LDL did not decrease by more than 10% from baseline in any of the five groups, and there was no statistically significant difference between any policosanol dose and placebo. Independent trials in several other countries reached the same conclusion.
The likely explanation combines methodological problems in the original trials, formulation issues, and the well-documented pattern that research from a single group with aligned commercial interests — here, a state-owned pharmaceutical industry — often fails to replicate when independent investigators apply the same test. Trial count is not evidence quality. Effect size is not evidence quality. Independent replication is what separates a real cardiovascular intervention from a commercial product that markets like one. The “who funded this, and is the research independent?” question from the Article 1 framework exists precisely because of patterns like this one.
The Compounds
Alpha-Lipoic Acid
Alpha-lipoic acid is a naturally occurring compound the body uses both as an antioxidant and as part of the energy-production machinery inside cells. Unlike most antioxidants, it is active in both water-based and fat-based cellular compartments, and it helps regenerate other antioxidants.
Where the evidence is strongest. Alpha-lipoic acid is a registered medicinal product in Germany for diabetic peripheral neuropathy — the painful nerve damage that develops in poorly controlled diabetes. In the SYDNEY 2 trial, 181 patients received oral alpha-lipoic acid at 600, 1,200, or 1,800 mg daily or placebo for five weeks, and treatment improved both neuropathic symptoms and deficits, with 600 mg/day identified as the best risk-to-benefit dose. (1) This is a defined clinical indication.
Cardiovascular evidence. Small studies show modest improvements in blood-vessel function in people with diabetes or metabolic syndrome, along with small effects on fasting glucose. No trial has tested whether alpha-lipoic acid prevents cardiovascular events.
Safety. Generally well tolerated. It may lower blood glucose in people on diabetes medications. Some reports raise the possibility of effects on thyroid hormone at higher doses; people with thyroid conditions can discuss this with their physician.
Honest position. Reasonable for diabetic nerve pain. Cardiovascular outcome evidence does not exist.
Chromium
Chromium is a trace mineral involved in the body’s response to insulin. The cardiovascular case rests on a chain of reasoning: chromium supports insulin signaling, insulin resistance underlies metabolic syndrome and type 2 diabetes, so improving insulin sensitivity should in theory reduce cardiovascular risk.
What the evidence shows. A systematic review of 41 trials found that among people with type 2 diabetes, chromium improved HbA1c (a marker of average blood sugar over months) by about 0.6% (95% CI 0.2–0.9) and lowered fasting glucose, but had no significant effect on lipids. (2) The HbA1c effect is smaller than what prescription diabetes medications achieve, and the review noted that almost half the included trials were of poor quality. There are no cardiovascular outcome data.
True chromium deficiency is rare in developed countries, and the modest glucose effects seen in trials may reflect partial correction of deficiency in some people rather than a benefit in everyone.
Honest position. May modestly improve glucose control in type 2 diabetes. (2) Not a substitute for proven diabetes medications. Cardiovascular benefit unproven.
Cinnamon
Cinnamon’s cardiovascular case mirrors chromium’s: traditional use for metabolic conditions, laboratory evidence of effects on insulin signaling, and a glucose-lowering signal in some human trials.
What the evidence shows. A meta-analysis of 10 randomized trials (543 patients with type 2 diabetes) found that cinnamon significantly reduced fasting plasma glucose, total cholesterol, LDL cholesterol, and triglycerides, and raised HDL — but produced no significant change in HbA1c. (3) Other meta-analyses are less consistent, with some finding HbA1c reductions and others finding none, so the overall picture across the literature is mixed rather than settled. There are no cardiovascular outcome data.
The safety distinction worth knowing. Most grocery-store cinnamon is cassia, which contains coumarin — a compound that is hepatotoxic at sustained high intake. European food-safety authorities set a tolerable daily intake for coumarin of 0.1 mg per kg of body weight on the basis of liver toxicity, and cassia cinnamon contains roughly 250 times more coumarin than Ceylon cinnamon. (12) For anyone considering daily cinnamon supplementation, this distinction matters; culinary amounts in food are not the concern, but concentrated daily cassia supplements can be.
Honest position. Glucose and lipid effects are present in some analyses but inconsistent across the literature. Not a substitute for proven therapies. Cardiovascular benefit unproven.
Nattokinase
Nattokinase is an enzyme derived from natto, a fermented soybean food traditional in Japan. It dissolves fibrin — the protein scaffold of blood clots — and the cardiovascular hypothesis is direct: clots cause most heart attacks and strokes, so dissolving or preventing them should reduce events.
What the evidence shows. Clot-dissolving activity is documented in laboratory studies and in human studies measuring coagulation parameters, and a review of nattokinase notes that it was undergoing a US clinical trial for atherothrombotic prevention. (4) A few small studies suggest a modest blood-pressure reduction, on the order of 5 mmHg systolic, and one small study suggested reduced atherosclerotic plaque progression that has not been replicated. No cardiovascular outcome trials exist.
The critical safety concern. The same clot-dissolving activity that is theoretically beneficial creates real bleeding risk. Combining nattokinase with anticoagulants (warfarin, DOACs) or antiplatelet drugs (aspirin, clopidogrel) produces additive bleeding effects with no proven cardiovascular benefit to justify the trade-off. (4) In patients on antithrombotic therapy, the combination warrants explicit discussion with the prescriber before use, and planned surgery would call for discontinuation in advance.
Honest position. A direct mechanism and no outcome evidence. The bleeding risk in patients on antithrombotic therapy is clinically real and argues against casual use in most cardiovascular patients — who are precisely the population most likely to be on those medications.
Taurine
Taurine is an amino acid concentrated in cardiac muscle, where it participates in calcium handling and antioxidant activity. Animal studies consistently show cardiovascular benefits. It is a common energy-drink ingredient, though the cardiovascular pharmacology of energy drinks is driven mainly by caffeine, not taurine.
What the evidence shows. A meta-analysis of 25 randomized trials (1,024 participants) found that taurine produced a modest systolic blood-pressure reduction of about 4 mmHg, a smaller diastolic reduction, and a reduction in triglycerides, with no significant effect on HDL. (10) Small studies also suggest possible improvement in heart-failure symptoms and exercise capacity. The trials are small and short-term, and there are no cardiovascular outcome data.
Safety. Well tolerated at doses up to about 3 grams daily, with no major safety concerns identified in these trials.
Honest position. The cardiac-muscle biology is of interest, and the surrogate signals are real but small. Human evidence is limited to small, short-term studies, and the case for cardiovascular prevention cannot be made without larger trial data.
L-Carnitine
L-carnitine is an amino acid derivative essential for transporting fatty acids into the energy-producing parts of cells. The heart relies heavily on fatty-acid metabolism and is rich in carnitine, and the cardiovascular hypothesis is that supplementation supports cardiac energy metabolism, particularly in high-demand conditions such as recovery after a heart attack.
What the evidence shows. A meta-analysis pooled 13 controlled trials (3,629 patients) of L-carnitine after acute myocardial infarction and reported a 27% reduction in all-cause mortality (odds ratio 0.73, 95% CI 0.54–0.99), a 65% reduction in ventricular arrhythmias, and a 40% reduction in angina, with no effect on heart failure or reinfarction. (5) Those numbers are striking on their face, but the same paper’s own sensitivity analysis shows why they should be read with caution: excluding the five smallest trials dropped the mortality benefit to non-significance (risk ratio 0.67, 95% CI 0.42–1.07, P=.09). The included trials were mostly older and small, and the authors called for an adequately powered modern trial. That trial has not been done. The signal is real; the evidence is contested.
The TMAO concern. Gut bacteria metabolize L-carnitine into trimethylamine-N-oxide (TMAO), a compound that promotes atherosclerosis in mice and is associated with increased cardiovascular risk in observational human studies. (6) Regular supplementation raises TMAO in people with the relevant gut bacteria, though the effect varies substantially by individual microbiome, and vegetarians and vegans produce far less TMAO from carnitine. Whether the elevation is clinically meaningful remains unresolved.
Honest position. The most mixed evidence in this article: a positive meta-analysis whose mortality signal does not survive removal of its weakest trials, set against an unresolved TMAO concern. (5,6) Modern outcome trials are needed and have not been done.
Lycopene
Lycopene is the carotenoid that gives tomatoes, watermelon, and other red produce their color. Higher lycopene intake is consistently associated with lower cardiovascular risk in observational studies. It accumulates in vascular tissue and has antioxidant properties relevant to LDL protection.
What the evidence shows. A meta-analysis of six intervention trials found that lycopene supplementation lowered systolic blood pressure by about 5 mmHg (−4.95 mmHg, 95% CI −8.82 to −1.09), with no significant effect on diastolic pressure and a stronger effect at doses above 12 mg/day and in people with higher baseline blood pressure. (7) LDL effects across studies are inconsistent. There are no cardiovascular outcome trials.
The food-supplement distinction applies clearly here. The observational cardiovascular benefit linked to lycopene comes mainly from tomato products — sauce, paste, juice — which deliver lycopene alongside other nutrients, and cooking tomatoes with oil substantially enhances absorption. Whether isolated lycopene supplements reproduce the benefit of a tomato-rich dietary pattern has not been established (Article 17 covered the broader food-supplement gap for antioxidants in detail).
Honest position. The observational signal favors tomato-rich dietary patterns, which carry support and no safety concern; isolated lycopene supplements for cardiovascular prevention are unproven. (7)
Astaxanthin
Astaxanthin is a red-orange carotenoid found in salmon, shrimp, and certain algae, and laboratory assays rank it among the most potent antioxidants known. The cardiovascular hypothesis builds on antioxidant activity, protection against LDL oxidation, and improved blood-vessel function — the same hypothesis that failed for vitamin E and beta-carotene in Article 17.
What the evidence shows. A meta-analysis of eight randomized trials found that astaxanthin (6–20 mg/day) reduced triglycerides and increased HDL, with no significant effect on LDL or total cholesterol; the authors rated the certainty of this evidence as very low, citing risk of bias and heterogeneity. (11) Some studies report reduced inflammatory markers; blood-pressure effects are limited. There are no cardiovascular outcome trials.
The relevant context. Potent antioxidant activity in laboratory assays has not reliably translated into cardiovascular benefit in human trials, and in some cases — high-dose vitamin E, beta-carotene in smokers — it produced harm (Article 17). Astaxanthin’s antioxidant potency in test-tube studies does not predict its cardiovascular relevance in patients.
Honest position. Preliminary human evidence of very low certainty, and no outcome data. The antioxidant-supplement track record from Article 17 tempers enthusiasm here.
Probiotics
Probiotics are live microorganisms intended to benefit gut health. The gut-cardiovascular connection — discussed in Article 3’s gut-heart axis section — is an active research area: gut bacteria influence inflammation, metabolize nutrients into cardiovascular-relevant compounds including TMAO (6), and appear to affect blood pressure and lipid metabolism.
What the evidence shows. A meta-analysis of nine trials found that probiotics modestly lowered blood pressure, by about 3.6 mmHg systolic and 2.4 mmHg diastolic, with greater effects when baseline blood pressure was elevated, multiple species were used, the intervention lasted at least eight weeks, and the dose was high. (9) Some strain-specific studies also suggest small effects on lipids. Effects are strain-specific, inconsistent across studies, and absent for most commercial products, which have not been tested for cardiovascular endpoints.
The strain problem is fundamental. Different bacterial strains produce different effects, and a positive result with one strain does not transfer to another. Most commercial probiotics have not been evaluated for cardiovascular endpoints, so buying a probiotic for cardiovascular health without knowing the specific strains and their evidence base is spending money on an unknown exposure.
Safety. Generally safe for healthy people. Caution applies in people with weakened immune systems or central venous catheters.
Honest position. An emerging field of real interest. (9) Current cardiovascular evidence is preliminary, strain-specific, and insufficient for a recommendation. Worth watching as the microbiome research matures.
Policosanol
Discussed above as the cautionary tale of the category. (8) The independent-replication test was applied, and the effect did not survive it. By current evidence, policosanol does not lower cholesterol.
The Evidence at a Glance
| Compound | Strongest evidence | Effect on cardiovascular markers | Outcome data | Key consideration |
| Alpha-lipoic acid | Diabetic neuropathy (registered medicine in Germany) (1) | Modest glucose / endothelial | None | Glucose-lowering interaction; possible thyroid effects at high doses |
| Chromium | Modest glucose control in type 2 diabetes (2) | HbA1c ≈ 0.6%; no lipid effect | None | Smaller effect than diabetes medications |
| Cinnamon | Glucose and lipid effects, inconsistent across analyses (3) | Significant in one meta-analysis; mixed overall | None | Cassia coumarin / liver injury at high doses (12) |
| Nattokinase | Clot-dissolving activity (4) | Modest BP (≈ 5 mmHg systolic) | None | Bleeding risk with antithrombotics |
| Taurine | Cardiac-muscle biology; surrogate signals (10) | SBP ≈ 4 mmHg; triglycerides down | None | Small, short-term human data |
| L-carnitine | Post-MI signals, contested (5,6) | Variable | None | Mortality signal not robust; TMAO concern |
| Lycopene | Observational dietary signal (7) | SBP ≈ 5 mmHg | None | Tomato patterns favored; supplement gap unresolved |
| Astaxanthin | Antioxidant potency in vitro (11) | Triglycerides down, HDL up; very low certainty | None | Antioxidant-supplement track record (Article 17) |
| Probiotics | Strain-specific BP signal (9) | SBP ≈ 3.6 mmHg, strain-specific | None | Most commercial products untested for CV endpoints |
| Policosanol | None — replication failed (8) | None on independent testing | None | Does not lower cholesterol by current evidence |
The pattern is consistent across all ten compounds. Several have modest effects on blood pressure, glucose, or cholesterol that meet the threshold for statistical detection. None has been shown to prevent heart attacks, strokes, or cardiovascular death.
Two Patients, Same Supplement Aisle
Both profiles below are composites built from the populations studied in the trials this article reviews.
Patient A is a 64-year-old man with type 2 diabetes (HbA1c 7.4% on metformin) and painful diabetic nerve symptoms in both feet. He read about alpha-lipoic acid online, asks his endocrinologist whether to try it, and mentions that it is widely sold as a cardiovascular supplement.
The article he read blended two separate things. Alpha-lipoic acid has randomized evidence for diabetic peripheral neuropathy, registered medicinal status in Germany, and a clinical indication that matches his actual symptoms. (1) It also has cardiovascular-supplement marketing built on small studies of blood-vessel function and glucose handling — evidence that is preliminary, not outcome-trial proof. The cardiovascular framing is what reached him; the neuropathy framing is what the evidence supports. The reframing his endocrinologist can offer is that alpha-lipoic acid around 600 mg daily is reasonable for the nerve pain and will not change his cardiovascular trajectory. The interventions that change that trajectory are the ones any clinician would name in any patient: glycemic control, blood-pressure control, lipid management, smoking status, weight, activity, and dietary pattern.
Patient B is a 71-year-old woman with atrial fibrillation on warfarin (INR target 2–3, stable for two years) and atherosclerotic plaque on a recent carotid ultrasound, who wants to “do something natural” alongside her medications. She read that nattokinase is a natural blood thinner that dissolves arterial plaque and has started taking 2,000 fibrinolytic units daily.
This is the most directly concerning combination in the article. Nattokinase has documented clot-dissolving activity. (4) Warfarin produces anticoagulation by blocking vitamin K-dependent clotting factors. Taken together they produce additive bleeding effects with no proven cardiovascular benefit to justify the risk. The article described nattokinase as a “natural” blood thinner — which is exactly what it is, and that is the problem rather than the solution in her situation. She is already on a proven anticoagulant for a specific indication, and adding a second one without supervision risks bleeding events her cardiologist and primary-care doctor have no knowledge of. The course her clinicians would weigh is discontinuing the nattokinase, telling her cardiologist what she had been taking, and checking her INR ahead of the next scheduled draw.
How to Think About This Category
For every supplement in this article, the outcome-trial answer is the same: there are none. They may work. We do not know. For most, the evidence to settle the question will not be produced in any clinically meaningful timeframe, which places these decisions outside the framework that governs the rest of cardiovascular medicine. Statins reduce events, and trials show by how much. Antihypertensives reduce events, and trials show by how much. The supplements here do not have that data and likely never will, so the decision about whether to take one cannot be made by reading the trial. It has to be made another way.
Calibration is the substitute. The blood-pressure and cholesterol effects in the small studies that do exist are typically on the order of 3–5 mmHg systolic and 5–10 mg/dL LDL — real enough to detect statistically, small enough that in isolation they are unlikely to change cardiovascular risk substantially. For comparison, a standard antihypertensive lowers systolic pressure by roughly 8–15 mmHg, and a statin lowers LDL by 30–50%, often 50 mg/dL or more. The supplements in this article operate at a fraction of those magnitudes when they have any measurable effect at all. They may contribute modestly within a comprehensive approach, but they do not approach the effect sizes that drive cardiovascular event reduction in the trials that established the proven interventions.
Opportunity cost matters too. A supplement at $25–50 a month is several hundred dollars a year, and that money applied to dietary improvement, a gym membership, prescription copayments, or additional medical monitoring may produce more cardiovascular benefit than the supplement itself — particularly because the proven interventions have established effect sizes and the supplement does not.
Safety is not uniformly benign. Nattokinase carries meaningful bleeding risk in patients on antithrombotic therapy. (4) High-dose cassia cinnamon carries liver-injury concern. (12) L-carnitine raises an unresolved TMAO question. (6) Alpha-lipoic acid can affect glucose and possibly thyroid function. (1) “Generally safe” describes most of these compounds most of the time. It does not mean interaction-free or risk-free for every patient.
The foundation comes first. Before any decision about an unproven supplement, the proven cardiovascular prevention strategy — blood-pressure control, lipid management with statins where indicated, diabetes control, smoking cessation, physical activity, dietary patterns, weight management — is the part with outcome evidence. The supplements here are not. A supplement is, at most, an addition to a strong foundation rather than a substitute for one.
Common Misconceptions
“If a supplement is sold in major retailers and on Amazon, it must work.” Commercial availability is not evidence. Most supplements in this article are widely sold and have no cardiovascular outcome data. Policosanol was sold in more than 40 countries on the strength of research from a single Cuban group that did not replicate. (8) Retail availability reflects regulatory categorization and consumer demand, not clinical efficacy.
“More than 80 published trials must mean it works.” The Cuban policosanol group published more than 80 placebo-controlled trials reporting statin-comparable LDL reductions. (8) When independent investigators ran rigorous trials, the effect was not there. Trial count is not evidence quality; independent replication by groups without financial alignment to the product is what matters.
“Preliminary data is the same as proof.” Preliminary positive data is the reason to run rigorous trials, not a substitute for them. Most supplements here have preliminary data showing modest effects on blood pressure or cholesterol, and none has been tested in a trial designed to detect cardiovascular events. This series has shown repeatedly — for niacin, B vitamins, vitamin D, and antioxidants — that effects on these markers do not reliably predict outcome benefit.
“If a supplement is ‘natural,’ it must be safe.” Several supplements in this article carry meaningful safety considerations. Nattokinase adds bleeding risk in patients on anticoagulants. (4) High-dose cassia cinnamon contains coumarin and can injure the liver. (12) L-carnitine raises TMAO. (6) Alpha-lipoic acid affects blood glucose. (1) “Natural” is a marketing term, not a safety designation.
“Animal data showing benefit means the human supplement will work.” The single largest failure pattern in supplement research is animal-to-human translation. Resveratrol’s metabolic improvements in mice (Article 18) did not translate to humans. Antioxidant cardiovascular benefits in animal models (Article 17) did not translate and in some cases produced harm. Animal data justifies further research; it does not establish human efficacy.
“If a supplement isn’t proven to work, it must not work.” Not necessarily. Some compounds here may eventually prove useful in specific settings — taurine’s cardiac biology is of real interest, and specific probiotic strains for specific endpoints may yet be established. The problem is not that these supplements cannot work; it is that the evidence needed to know has not been produced and, for most, will not be. Uncertainty about benefit is not proof of no benefit. It is uncertainty, which is its own honest answer.
“Nothing is proven, so I might as well try things.” Uncertainty is not a free pass. The proven interventions — blood-pressure control, statins where indicated, diabetes management, smoking cessation, dietary patterns, physical activity — carry substantial outcome evidence. Spending on unproven supplements is not a neutral choice; it consumes resources and attention that could go to interventions with better evidence.
The Bottom Line
Across the ten compounds in this article, the evidence pattern is consistent. Each has a biological rationale — antioxidant activity, insulin signaling, clot dissolution, anti-inflammatory effects, vascular biology — that makes a cardiovascular benefit plausible. Each has small studies showing modest effects on blood pressure, cholesterol, glucose, or other risk markers. None has been tested in a randomized trial designed and powered to detect heart attacks, strokes, or cardiovascular death, and for most that trial will not be conducted in any meaningful timeframe, because the trial economics and patent structure that drive cardiovascular outcome research do not apply to unpatentable compounds. The result is a category of supplements that are neither proven to work nor proven not to work. The honest interpretation is uncertainty — not endorsement, and not dismissal.
The major cardiovascular guidelines reflect this. The 2018 ACC/AHA cholesterol guideline, the 2017 ACC/AHA hypertension guideline, the 2022 AHA/ACC/HFSA heart failure guideline, and the 2021 ESC prevention guideline do not include any supplement in this article among recommended interventions for cardiovascular event prevention.
| If you have… | What this means in practice |
| A non-cardiovascular indication that matches a compound | Alpha-lipoic acid for diabetic neuropathy or chromium as a modest glucose adjunct in type 2 diabetes may be reasonable for that indication, with expectations calibrated to what the trials show — not as cardiovascular event prevention (1,2) |
| A goal of preventing a heart attack or stroke | The trial evidence does not support any compound here for that purpose; the interventions that reduce events are blood-pressure control, lipid management with statins where indicated, diabetes control, antiplatelet therapy where indicated, smoking cessation, dietary patterns, weight management, and physical activity |
| Warfarin, a DOAC, antiplatelet therapy, digoxin, or established cardiovascular disease on multiple medications | Interaction risks are real; nattokinase plus an anticoagulant is a particularly clear combination to avoid, and cassia cinnamon, alpha-lipoic acid with diabetes medications, and L-carnitine warrant a prescriber conversation before starting (1,4,6,12) |
| Several hundred dollars a year going to these supplements | That money applied to dietary improvement, prescription copayments, a gym membership, or additional monitoring is likely to produce more cardiovascular benefit than the supplement itself |
The structural reality of this category will not change. The cardiovascular supplement aisle will keep offering compounds with biological plausibility, preliminary surrogate data, and no outcome trial evidence. The tools this series has built — the Ten Questions from Article 1, the two-question framework from Article 2, and the Outcomes Ladder from Article 3 — are what allow rational evaluation when the trial that would settle the question is not coming. The honest position is uncertainty. That is not the same as no answer. It is the answer.
Key Terms
Effect size: The magnitude of an intervention’s impact. Blood-pressure reductions of 3–5 mmHg and LDL changes of 5–10 mg/dL are the typical effect sizes in this category — real enough to detect statistically, modest enough that the clinical significance for an individual’s cardiovascular risk is uncertain.
Fibrinolysis: The dissolving of blood clots. Nattokinase has fibrinolytic activity in laboratory studies; whether that translates into event reduction has not been tested in cardiovascular outcome trials.
Independent replication: Reproduction of a research finding by investigators without financial or institutional alignment to the original group. The policosanol case shows why it matters: a single group published more than 80 trials reporting statin-comparable cholesterol reduction, and independent investigators found no effect.
Mechanistic rationale: Biological reasoning for why an intervention might work. Necessary to justify research, but not sufficient to justify a clinical recommendation.
Opportunity cost: What is given up when resources are committed elsewhere. In supplement decisions, money spent on unproven products is unavailable for proven interventions, dietary improvement, or medical monitoring.
Outcome trial: A randomized study measuring clinical events — heart attacks, strokes, cardiovascular death — rather than laboratory markers. The standard this series applies. No supplement in this article meets it.
Surrogate marker: A measurable lab value — blood pressure, cholesterol, glucose — used as a proxy for clinical outcomes. Improving a surrogate does not guarantee improving outcomes, as the niacin, homocysteine, vitamin D, and antioxidant articles in this series have shown.
Trimethylamine-N-oxide (TMAO): A metabolite produced when gut bacteria break down L-carnitine, choline, and related compounds. It promotes atherosclerosis in animal models and is associated with increased cardiovascular risk in observational human studies. The unresolved TMAO question complicates L-carnitine supplementation specifically.
References
- Ziegler D, Ametov A, Barinov A, et al. Oral treatment with α-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006;29(11):2365–2370.
- Balk EM, Tatsioni A, Lichtenstein AH, Lau J, Pittas AG. Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials. Diabetes Care. 2007;30(8):2154–2163.
- Allen RW, Schwartzman E, Baker WL, Coleman CI, Phung OJ. Cinnamon use in type 2 diabetes: an updated systematic review and meta-analysis. Ann Fam Med. 2013;11(5):452–459.
- Weng Y, Yao J, Sparks S, Wang KY. Nattokinase: an oral antithrombotic agent for the prevention of cardiovascular disease. Int J Mol Sci. 2017;18(3):523.
- DiNicolantonio JJ, Lavie CJ, Fares H, Menezes AR, O’Keefe JH. L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis. Mayo Clin Proc. 2013;88(6):544–551.
- Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19(5):576–585.
- Li X, Xu J. Lycopene supplement and blood pressure: an updated meta-analysis of intervention trials. Nutrients. 2013;5(9):3696–3712.
- Berthold HK, Unverdorben S, Degenhardt R, Bulitta M, Gouni-Berthold I. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. JAMA. 2006;295(19):2262–2269.
- Khalesi S, Sun J, Buys N, Jayasinghe R. Effect of probiotics on blood pressure: a systematic review and meta-analysis of randomized, controlled trials. Hypertension. 2014;64(4):897–903.
- Tzang C-C, et al. Taurine reduces the risk for metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials. Nutr Diabetes. 2024;14(1):29.
- Barbalho SM, et al. Assessing the effects of moderate to high dosage of astaxanthin supplementation on lipid profile parameters: a systematic review and meta-analysis of randomized controlled studies. Pharmaceuticals (Basel). 2025;18(8):1097.
- European Food Safety Authority (EFSA). Coumarin in flavourings and other food ingredients with flavouring properties. EFSA J. 2008;6(10):793.
HeartBuddi • Your heart. Own it. • This article is part of an evidence-based educational series and is not a substitute for individualized medical advice.